Praecis Puts Brakes On Plenaxis, Explores Strategic Financing Options
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will record $7.5 mil. in charges after announcing it will not enter a licensing or sale transaction for the prostate cancer therapy.
You may also be interested in...
GSK Shopping Spree Continues With Praecis Acquisition
Latest deal could bring GSK’s total price tag for December to almost $4 billion.
Future BIO Global Efforts Include International Relations, Greenwood Says
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13